HER2 EXPRESSION IN GASTRIC ADENOCARCINOMA

Trần Ngọc Thụy; Nguyễn Phú Hùng; Dương Hồng Thái

doi:10.34238/tnu-jst.8835

HER2 EXPRESSION IN GASTRIC ADENOCARCINOMA

About this article

Received: 26/09/23 Revised: 30/10/23 Published: 07/11/23

Authors

1. Tran Ngoc Thuy , TNU - University of Medicine and Pharmacy
2. Nguyen Phu Hung, TNU - University of Sciences
3. Duong Hong Thai, TNU - University of Medicine and Pharmacy

Abstract

This study evaluated the level of HER2 expression and its relationship with the endoscopic and histopathological features of patients with gastric adenocarcinoma. The cross-sectional descriptive research method was performed on 150 patients with a confirmed diagnosis of gastric adenocarcinoma at K Hospital from January 2018 to December 2019. The study results showed that the rate of HER2 positive in 28.7% of gastric adenocarcinoma cases. According to the Borrmann classification, the rate of HER2 is positive in ulcerater (32.5%), fungating (27.8%), infiltrates (16.7%) and polyp (0%), (p > 0.05). According to Lauren's histopathological classification, the rate of HER2 positivity in the indeterminate type (42.9%) is higher than that of the intestinal type (33%) and diffuse type (11.8%), (p < 0.05). According to the histological classification of the World Health Organization, the rate of HER2 positivity is in papillary (66.7%), mixed (42.9%), mucinous (38.9%), tubular (30.7%) and signet-ring cell (11.8%) with p < 0.05. Rate of HER2 positivity according to differentiation: Well-differentiated tumors (51.7%), moderately differentiated tumorrs (30.4%) and poorly differentiated tumors (16,9%) with p < 0.05. HER2 expression in patients with gastric adenocarcinoma is associated with histopathological characteristics according to the classification of Lauren and the World Health Organization.

Keywords

Gastric adenocarcinoma; HER2; Endoscopy; Tubular adenocarcinoma; Immunohistochemistry

Full Text:

PDF (Tiếng Việt)

References

[1] H. Sung, J. Ferlay, and R. L. Siegel, "Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries," CA Cancer J Clin, vol. 71, no. 3, pp. 209-249, 2021.

[2] Y. Li, A. Feng, S. Zheng, C. Chen, and J. Lyu, "Recent Estimates and Predictions of 5-Year Survival in Patients with Gastric Cancer: A Model-Based Period Analysis," Cancer Control, vol. 29, 2022, Art. no. 10732748221099227.

[3] J. Sastre, J. A. Garcia-Saenz, and E. Diaz-Rubio, "Chemotherapy for gastric cancer," World journal of gastroenterology, vol. 12, no. 2, pp. 204-213, 2006.

[4] K. Yamashita, K. Hosoda, M. Niihara, and N. Hiki, "History and emerging trends in chemotherapy for gastric cancer," Annals of gastroenterological surgery, vol. 5, no. 4, pp. 446-456, 2021.

[5] P. H. Nguyen and T. T. .H. Le, "Acetylcholine stimulates the cell proliferation and increases the expression of cancer stem cell markers in the gastric cancer cell line mkn74," TNU Journal of Science and Technology, vol. 226, no. 10, pp. 255-260, 2021.

[6] V. A. Le, H. T. Duong, and P. H. Nguyen, "Relationship between simultaneous expression of aldh and kras with histopathological features in gastric cancer," TNU Journal of Science and Technology, vol. 228, no. 9, pp. 465-470, 2023.

[7] A. Pellino, E. Riello, F. Nappo, S. Brignola, S. Murgioni, S. A. Djaballah et al., "Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives," World J Gastroenterol, vol. 25, no. 38, pp. 5773-5788, 2019.

[8] J. T. Jorgensen and M. Hersom, "HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature," J Cancer, vol. 3, no. 1, pp. 137-144, 2012.

[9] C. Ma, X. Wang, J. Guo, B. Yang, and Y. Li, "Challenges and future of HER2-positive gastric cancer therapy," Frontiers in oncology, vol. 13, 2023, Art. no. 1080990.

[10] A. Pous, L. Notario, C. Hierro, L. Layos, and C. Buges, "HER2-Positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies," International journal of molecular sciences, vol. 24, no. 14, 2023, Art. no. 11403.

[11] N. Boku, "HER2-positive gastric cancer," Gastric Cancer, vol. 17, no. 1, pp. 1-12, 2014.

[12] C. Díaz Del Arco, L. Ortega Medina, L. Estrada Munoz, E. Molina Roldán, M. Cerón Nieto, S. García Gómez de Las Heras et al., "Are Borrmann's Types of Advanced Gastric Cancer Distinct Clinicopathological and Molecular Entities? A Western Study," Cancers Basel, vol. 13, no. 12, 2021, Art. no. 3081.

[13] I. D. Nagtegaal, R. D. Odze, D. Klimstra, V. Paradis, M. Rugge, P. Schirmacher et al., "The 2019 WHO classification of tumours of the digestive system," Histopathology, vol. 76, no. 2, pp. 182-188, 2019.

[14] M. B. Amin, F. L. Greene, S. B. Edge, C. C. Compton, J. E. Gershenwald, R. K. Brookland et al., "The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more personalized," CA Cancer J Clin, vol. 67, no. 2, pp. 93-99, 2017.

[15] V. N. Le, "Studying the expression of egfr, her2 and their relationship with clinical, endoscopic, histopathological characteristics in patients with gastric adenocarcinoma," PhD. Thesis, Hue University Medicine and Pharmacy, Hue, 2014.

[16] M. A. Pham and T. T. Le, "Study status of the human epidermal growth factor receptor 2 overexpression with histopathology of gastric cancer," Vietnam medical journal, vol. 516, no. 1, pp. 147-152, 2022.

[17] G. Z. Yu, Y. Chen, and J. J. Wang, "Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance," J Cancer Res Clin Oncol, vol. 135, no. 10, pp. 1331-1339, 2009.

[18] H. R. Lee, J. H. Kim, H. D. Uhm, J. B. Ahn, S. Y. Rha, J. Y. Cho et al., "Overexpression of c-ErbB-2 protein in gastric cancer by immunohistochemical stain," Oncology, vol. 53, no. 3, pp. 192-197, 1996.

[19] H. Allgayer, R. Babic, K. U. Gruetzner, A. Tarabichi, F. W. Schildberg, and M. M. Heiss, "C-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems," J Clin Oncol, vol. 18, no. 11, pp. 2201-2209, 2000.

[20] S. Y. Yan, Y. Hu, J. G. Fan, G. Q. Tao, Y. M. Lu, X. Cai et al., "Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma," World J Gastroenterol, vol. 17, no. 11, pp. 1501-1506, 2011.

[21] Y. Kataoka, H. Okabe, A. Yoshizawa, S. Minamiguchi, K. Yoshimura, H. Haga et al., "HER2 expression and its clinicopathological features in resectable gastric cancer," Gastric Cancer, vol. 16, no. 1, pp. 84-93, 2013.

[22] R. I. Nicholson, J. M. Gee, and M. E. Harper, "EGFR and cancer prognosis," Eur J Cancer, vol. 4, no. 1, pp. 9-15, 2001.

DOI: https://doi.org/10.34238/tnu-jst.8835

Refbacks

There are currently no refbacks.



Remember me